Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis
Metrics: PDF 918 views | HTML 1297 views | ?
Wang Fangzheng1,2,3,*, Jiang Chuner4,*, Ye Zhimin1,2, Sun Quanquan1,2, Liu Tongxin1,2, Xu Min5, Wu Peng6, Long Bin7, Masoto Sakamoto3, Wang Yuezhen1,2, Yan Fengqin1,2, Fu Zhenfu1,2 and Jiang Yangming8
1Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Hangzhou 310022, People’s Republic of China
2Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Hangzhou 310022, People’s Republic of China
3Department of Radiology, Japanese Red Cross Fukui Hospital, Fukui 918-8501, Japan
4Department of Breast Tumor Surgery, Zhejiang Cancer Hospital, Zhejiang Hangzhou 310022, People’s Republic of China
5Department of Physics, Zhejiang Cancer Hospital, Zhejiang Hangzhou 310022, People’s Republic of China
6Department of Pathology, Zhejiang Cancer Hospital, Zhejiang Hangzhou 310022, People’s Republic of China
7Department of Nuclear Medicine, Zhejiang Cancer Hospital, Zhejiang Hangzhou 310022, People’s Republic of China
8Department of Didital Earth, Institute of Remote Sensing and Didital Earth, CAS, Beijing 100101, People’s Republic of China
*These authors have contributed equally to this work
Jiang Yangming, email: email@example.com
Wang Fangzheng, email: firstname.lastname@example.org
Keywords: nasopharyngeal carcinoma, neoadjuvant chemotherapy, cycle, survival outcomes, prognosis
Received: July 18, 2017 Accepted: September 21, 2017 Published: October 06, 2017
Neoadjuvant chemotherapy (NAC) is widely used to treat locoregionally advanced nasopharyngeal carcinoma (NPC). To determine the optimal number of NAC cycles, we assessed the effect of NAC cycle on survival outcomes of locoregionally advanced NPC patients receiving NAC before concurrent chemotherapy and intensity-modulated radiotherapy. Clinical data from 1,188 non-metastatic NPC patients were retrospectively reviewed. All received ≥2 cycles of NAC added to concurrent chemoradiotherapy. Propensity score matching (PSM) was used to identify paired patients according to various covariates. In total, 297 pairs were selected. After a median follow-up time of 57 months (range: 7 to 104 months), the 5-year locoregional relapse-free survival, distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival rates in patients treated with 2 cycles vs. 3 to 4 cycles of NAC were 91.3% vs. 87.2% (P=0.149), 93.3% vs. 88.5% (P=0.043), 88.7% vs. 81.7% (P=0.037), and 94.0% vs. 92.6% (P=0.266), respectively. On multivariate analysis, 2 cycles of NAC were associated with improved DMFS (hazard ratio, 0.499; P=0.038) and PFS (hazard ratio, 0.585; P=0.049). NAC cycle was an independent prognosticator of DMFS and PFS in univariate and multivariate analyses. Thus, 2 cycles of NAC appear sufficient, as additional cycles were not associated with added survival benefit for locoregionally advanced NPC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.